Abstract
As all the novelties, the biotechnological and genetic industry causes problems of intellectual property. Moreover, the genes are very special things, not only because they touch to the living, but because they are carrying hopes (new therapies, drugs...) and fears too (protection of the Human body, protection of the collected data...).
The main problem is to find an equilibrium between the incentive to innovate and the diffusion of the information and the knowledge in the sensible sector of the genetic. Thus, the authority tried to insert the problem of the patentability of the living (in general) and genes (in particular) in the preexistent intellectual property protection system: the patents system.
